Example: Heart Attack

Search clinical trials for: 131I-MIBG

Total 21 results

NCT03561259

Recruiting

A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects (OPTIMUM)

Neoplasms | Neuroectodermal Tumors | Neuroblastoma
NCT03126916

Recruiting

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Neuroblastoma | Ganglioneuroblastoma
NCT03332667

Active, not recruiting

MIBG With Dinutuximab +/- Vorinostat

Neuroblastoma
NCT03044977

Active, not recruiting

Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors

Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting | Neuroendocrine Tumor, Malignant
NCT01163383

Available

131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol

Neuroblastoma | Childhood Metastatic Pheochromocytoma
NCT01370330

Available

131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol

Neuroblastoma
NCT03015844

Available

A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma

Neuroblastoma | Pheochromocytoma
NCT00253435

Completed

N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma

Neuroblastoma
NCT01175356

Active, not recruiting

Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin

Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Ganglioneuroblastoma | Stage 4 Neuroblastoma
NCT01850888

Suspended

MIBG for Refractory Neuroblastoma and Pheochromocytoma

Relapsed Neuroblastoma | Metastatic Pheochromocytoma
NCT02035137

Completed

131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat (N2011-01)

Neuroblastoma
NCT03649438

No longer available

131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma

Relapsed Neuroblastoma | Metastatic Pheochromocytoma
NCT01377532

Approved for marketing

Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma

Pheochromocytoma | Paraganglioma
NCT01313936

Completed

High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma

Neuroblastoma
NCT03061656

Unknown

Tandem High Dose Chemotherapy With 131I-MIBG Treatment in High Risk Neuroblastoma

High Risk Neuroblastoma
NCT01413503

Completed

A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors

Pheochromocytoma | Paraganglioma
NCT00028106

Completed

131MIBG to Treat Malignant Pheochromocytoma

Pheochromocytoma
NCT00555984

Withdrawn

Intravenous Anesthesia Versus Anesthesia With Volatile Agents in Elective Craniotomy for Tumors (TIVA)

Brain Neoplasms
NCT01941849

Withdrawn

Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma (VIBRaNT)

Paraganglioma | Phaeochromocytoma
NCT00798148

Unknown

131I-MIBG With Myeloablative Chemotherapy and Autologous Stem Cell Transplantation for the Treatment of High-risk Neuroblastoma

Neuroblastoma
NCT00013806

Unknown

CHP677: I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma: a Phase II Study

Neuroblastoma

Search clinical trials for: 131I-MIBG

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uruguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations